PMID: 42905Nov 1, 1979

Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein

Proceedings of the National Academy of Sciences of the United States of America
J E SealeyA P Kaplan

Abstract

Plasma prorenin is an inactive form of renin (EC 3.4.99.19) that can be converted to active renin in acid-treated plasma by an endogenous serine protease that is active at alkaline pH (alkaline phase activation). To identify this enzyme we first tested the ability of Hageman factor fragments, plasma kallikrein (EC 3.4.21.8), and plasmin (EC 3.4.21.7) to activate prorenin in acid-treated plasma. All three enzymes initiated prorenin activation; 50% activation was achieved with Hageman factor fragments at 1 microgram/ml, plasma kallikrein at 2-4 microgram/ml, or plasmin at 5-10 microgram/ml. We then showed that the alkaline phase of acid activation occurred normally in plasminogen-free plasma but was almost completely absent in plasmas deficient in either Hageman factor or prekallikrein; alkaline phase activation was restored to these latter plasmas when equal parts were mixed together. Therefore, both Hageman factor and prekallikrein were required for alkaline phase activation to occur. We then found that, although plasma kallikrein could activate prorenin in plasma deficient in either Hageman factor or prekallikrein, Hageman factor fragments were unable to activate prorenin in prekallikrein-deficient plasma. These studies demons...Continue Reading

References

Mar 1, 1988·Somatic Cell and Molecular Genetics·N J RoyleJ L Hamerton
Jan 1, 1985·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·G PatrassiF H Derkx
Jan 15, 1981·Biochimica Et Biophysica Acta·C H Lawrence, B J Morris
Sep 27, 2000·Biochimica Et Biophysica Acta·P C AlmeidaL Juliano
Jan 1, 1983·Journal of the American College of Cardiology·E D Frohlich
Jan 1, 1986·Critical Reviews in Oncology/hematology·R W Colman, Alvin H Schmaier
Oct 1, 1989·DNA·N G SeidahM Chrétien
Apr 10, 2008·Journal of Hypertension·M P SchalekampAh Jan Danser
May 1, 1984·The Journal of Clinical Investigation·R W Colman
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·K ChimoriK Miura
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·H OhashiC Kawai
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·F ManteroA Girolami
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·E J Leckie
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·F H DerkxM P Schalekamp
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·E Haber, W Carlson
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·F H DerkxM A Schalekamp
May 15, 1981·Biochemical Pharmacology·D R BorgesJ L Prado
Jan 1, 1982·Annals of the New York Academy of Sciences·A P KaplanB Ghebrehiwet
Jul 24, 2007·Biomaterials·Rui ZhuoErwin A Vogler
Dec 25, 1980·Nature·B J Leckie, N K McGhee
Jan 1, 1987·British Journal of Obstetrics and Gynaecology·F H DerkxM P Schalekamp
Apr 9, 2015·Cardiology in Review·Mark Carpenter, Hannah Sinclair
Jun 10, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alvin H Schmaier
Jul 3, 2019·International Journal of Molecular Sciences·Ryan D SullivanInna P Gladysheva
Nov 1, 1990·Blut·G FuhrerH E Hoffmeister

Citations

Aug 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·T M LincolnJ D Corbin
Nov 1, 1976·The American Journal of Medicine·J E SealeyM Alderman
Jun 17, 1978·Lancet·S R Tatemichi, D H Osmond
Dec 1, 1975·The Journal of Clinical Investigation·K D WuepperM J Lacombe
Jun 1, 1975·The Journal of Clinical Endocrinology and Metabolism·R P DayC M Gonzales
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·R C WigginsJ H Griffin
Oct 1, 1978·Canadian Journal of Physiology and Pharmacology·D H Osmond, R M Cooper
Jul 1, 1977·The Journal of Clinical Investigation·C Y LiuR W Colman
Dec 1, 1977·The Journal of Clinical Investigation·R E ThompsonA P Kaplan
Nov 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·R J MandleA P Kaplan
Apr 29, 1969·Biochemical and Biophysical Research Communications·R W Colman
Jun 1, 1965·Archives of Biochemistry and Biophysics·E HaasE C Gipson
Dec 7, 1972·Biochimica Et Biophysica Acta·B J Morris, E R Lumbers
Dec 1, 1973·The Journal of Experimental Medicine·K D Wuepper
Apr 1, 1955·The Journal of Clinical Investigation·O D RATNOFF, J E COLOPY

Related Concepts

F12
PLG
Plasma Prokallikrein A
AGT
Fibrogammin
Prekallikrein Deficiency
KLKB1
REN
Hydrogen-Ion Concentration
Factor XII

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.